Prostate cancer, due to wide availability of PSA tests, is very often diagnosed in early stage, nowadays.
This makes management of this disease even harder in every day oncology care. There is a wide range of treatment options including surgery, radiotherapy and active surveillance, but essential question is which treatment patient and oncologist should decide for. Due to recent publication of Prostate Cancer Results Study Group, in which brachytherapy is one of supreme curative options for prostate cancer, we decided to overview most present european and north american recommendations. National Comprehensive Cancer Network, American Society for Radiation Oncology, American Brachytherapy Society, European Association of Urology and Groupe Européen de Curiethérapie of European Society for Therapeutic Radiation Oncology guidelines are overviewed, particularly focusing on HDR and LDR brachytherapy.
Written by:
Wojcieszek P, Białas B. Are you the author?
Brachytherapy Department, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland.
Reference: J Contemp Brachytherapy. 2012 Jun;4(2):116-20.
doi: 10.5114/jcb.2012.29370
PubMed Abstract
PMID: 23349655
UroToday.com Prostate Cancer Section
